Dr Reddys Laboratories Allots 12,100 Shares Following Stock Option Exercise
Dr Reddy's Laboratories Ltd has allotted 12,100 equity shares in connection with the exercise of stock options under its Employee Stock Options Scheme (ESOP) and ADR Stock Options Scheme. The allotment was completed on June 5, 2026.The allocation pertains to eligible employees exercising their rights under both Dr. Reddy's Employees Stock Options Scheme, 2002, and Dr. Reddy's Employees ADR Stock Options Scheme, 2007. These shares were issued at a face value of Re. 1/- each and carried no premium.
The issuance updates the company’s share capital structure following this transaction. The total number of issued shares after the allotment reached 83,46,70,070. Consequently, the total issued share capital stood at Rs. 83,46,70,070/-.
Key details regarding the allotment and corporate share information are presented below:
| Detail | Information |
|---|---|
| Date of Allotment | June 5, 2026 |
| Number of Shares Issued | 12,100 equity shares |
| Par Value per Share | Re. 1/- |
| Exercise Price per Share | Re. 1/- |
| Premium per Share | NIL |
| Total Issued Shares (Post-Allotment) | 83,46,70,070 |
| Total Issued Share Capital | Rs. 83,46,70,070/- |
The issued shares rank pari passu with the existing shares of the company. The allotment is an extension of the long-standing schemes established under Dr. Reddy's Employees Stock Options Scheme, 2002, and Dr. Reddy's Employees ADR Stock Options Scheme, 2007.
DRREDDY Stock Price Movement
Today, Dr. Reddy's Laboratories Limited shares edged higher in post-market trading, settling at ₹1283 after the stock gained 1.22%. The company saw a robust volume of 774,686 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.